Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGINE: Clazakizumab for Chronic Active Antibody-mediated Rejection
NCT03744910Phase 3Terminated
- Sponsor
- CSL Limited
- Start
- Oct 2019
- Primary completion
- Apr 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of clazakizumab in antibody mediated rejection (AMR), sponsored by CSL Limited. Started Oct 2019; status: terminated.
02
Drugs
clazakizumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT03744910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744910.